In early-stage disease, adjuvant alectinib benefits resected ALK-positive NSCLC (April 2024), and adjuvant osimertinib improves overall survival (July 2023) in resected EGFR-mutant NSCLC [30,31]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.